Under the same assay condition, however, plasma TROP2 levels did not maintain significant difference between CRC patients and controls (53.37 ± 12.27 ng/mL versus 57.11 ± 15.02 ng/mL; p = 0.31, independent t-test; Figure 1(b), right panel). The gene discussed is TACSTD2; the disease is colorectal carcinoma.